miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Biomarkers

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3233/CBM-150545PMID 26835710
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• miR-638 mediated regulation of BRCA1affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer

  2014cited by this paper
• MicroRNAs Expression in Triple Negative vs Non Triple Negative Breast Cancer in Tunisia: Interaction with Clinical Outcome

  2014cited by this paper
• The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis

  2014cited by this paper
• Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer

  2014cited by this paper
• MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma

  2014cited by this paper
• BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function

  2014influential reference
• Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis

  2013cited by this paper
• Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation

  2013cited by this paper
• miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.

  2013cited by this paper
• MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.

  2013cited by this paper
• BRCA1 and MicroRNAs: Emerging networks and potential therapeutic targets

  2012cited by this paper
• Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation.

  2012cited by this paper
• Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice

  2011cited by this paper
• Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

  2011cited by this paper
• Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers

  2011cited by this paper
• Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

  2011cited by this paper
• The Impact of miRNA Target Sites in Coding Sequences and in 3′UTRs

  2011cited by this paper
• CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer

  2011cited by this paper
• MicroRNA-146a Downregulates NFκB Activity via Targeting TRAF6 and Functions as a Tumor Suppressor Having Strong Prognostic Implications in NK/T Cell Lymphoma

  2011cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients.

  2010cited by this paper
• Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.

  2010cited by this paper
• Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.

  2010cited by this paper
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.

  2009cited by this paper
• Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas

  2009cited by this paper
• Triple‐negative/basal‐like breast cancer: review

  2009cited by this paper
• Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers

  2009cited by this paper
• Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer

  2009cited by this paper
• Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells

  2008cited by this paper
• Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

  2008cited by this paper
• Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

  2008cited by this paper
• Expression of BRCA1 protein in breast cancer and its prognostic significance.

  2008cited by this paper
• Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors

  2008influential reference
• A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.

  2008cited by this paper
• Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers

  2008cited by this paper
• Triple-negative breast cancer.

  2008cited by this paper
• Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

  2007cited by this paper
• Prognostic markers in triple‐negative breast cancer

  2007cited by this paper
• Triple negative tumours: a critical review

  2007influential reference
• A microRNA expression signature of human solid tumors defines cancer gene targets

  2006cited by this paper
• Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations

  2005cited by this paper
• Haplo-insufficiency of BRCA1 in sporadic breast cancer.

  2003cited by this paper
• Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR

  2002cited by this paper
• Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation

  1999cited by this paper
• Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells

  1998cited by this paper
• Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody.

  1986cited by this paper
• ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy

  1969cited by this paper

• Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis

  2024cites this paper
• Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells

  2024cites this paper
• miRNAs in the prognosis of triple-negative breast cancer: A review.

  2023cites this paper
• ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!

  2023cites this paper
• miR-638: A Promising Cancer Biomarker with Therapeutic Potential.

  2022cites this paper
• miR-638 Serves as a Biomarker of 5-Fluorouracil Sensitivity to Neoadjuvant Chemotherapy in Breast Cancer

  2022influential citation
• The Role of miRNAs in the Prognosis of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

  2022cites this paper
• Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer.

  2022cites this paper
• Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness

  2022cites this paper
• The associations and roles of microRNA single-nucleotide polymorphisms in cervical cancer

  2021cites this paper
• Dysregulation of miR-638 in the progression of cancers.

  2021cites this paper
• Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment

  2020cites this paper
• Effect and mechanism of miR-146a on malignant biological behaviors of lung adenocarcinoma cell line

  2020cites this paper
• Small RNA biosensor design strategy to mitigate off-analyte response.

  2020cites this paper
• MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review

  2020cites this paper
• miR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma.

  2020cites this paper
• MicroRNAs in breast cancer: Roles, functions, and mechanism of actions

  2019cites this paper
• Downregulation of miR-136 promotes the progression of osteosarcoma and is associated with the prognosis of patients with osteosarcoma.

  2019cites this paper
• Protective potential of miR-146a-5p and its underlying molecular mechanism in diverse cancers: a comprehensive meta-analysis and bioinformatics analysis

  2019cites this paper
• Prognostic role of microRNAs in breast cancer: A systematic review

  2019cites this paper
• Dysregulation of miR-638 in Breast Cancer Patients and Bioinformatics Investigation of Its Target Genes in Apoptosis, Angiogenesis and Autophagy Pathways

  2019cites this paper
• miR-146 a promotes cervical cancer cell viability via targeting IRAK 1 and TRAF 6

  2018cites this paper
• CTBP 1 and metabolic syndrome induce an mRNA and miRNA expression profile critical for breast cancer progression and metastasis

  2018cites this paper
• Downregulation of miR-638 promotes progression of breast cancer and is associated with prognosis of breast cancer patients

  2018cites this paper
• MicroRNAs in triple-negative breast cancer.

  2018cites this paper
• CTBP1 and metabolic syndrome induce an mRNA and miRNA expression profile critical for breast cancer progression and metastasis

  2018cites this paper
• Non-Coding RNAs as Future Cancer Biomarkers

  2018cites this paper
• MiR-146a inhibits proliferation and induces apoptosis in murine osteoblastic MC3T3-E1 by regulating Bcl2.

  2017cites this paper
• MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells

  2017cites this paper
• Transcription factor SLA 2 regulated genes predict the survival of breast cancer patients

  2017cites this paper
• MiR-146 a inhibits proliferation and induces apoptosis in murine osteoblastic MC 3 T 3E 1 by regulating Bcl 2

  2017cites this paper
• MicroRNA Therapeutics in Triple Negative Breast Cancer

  2017cites this paper
• Both plasma and tumor tissue miR-146a high expression correlates with prolonged overall survival of surgical patients with intrahepatic cholangiocarcinoma

  2017cites this paper
• The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation

  2017cites this paper
• MicroRNA expression in bone marrow-derived human multipotent Stromal cells

  2017cites this paper
• MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting the PDCD4.

  2016cites this paper
• RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

  2016cites this paper